Carolina Sotelo-Rodríguez (Carolina Sotelo)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Topics

African American

Advanced Non Small Cell Lung Cancer

Pulmonary Tuberculosis

Tyrosine Kinase

Top Venues

JCO global oncology

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Carolina Sotelo-Rodríguez, Dora Lucia Vallejo Ardila, Alejandro Ruíz-Patiño, Diego F Chamorro, July Rodríguez, Darwin A Moreno-Pérez, Hernán Carranza, Jorge Otero, Carlos Vargas, Pilar Archila, Leonardo Rojas, Jairo Zuluaga, Cladelis Rubio, Camila Ordóñez-Reyes, Juan Esteban Garcia-Robledo, Sergio Mejía, Elvira Jaller, Arrieta Oscar, Andrés F Cardona
Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors. JCO global oncology 10 (2024)
Carolina Sotelo-Rodríguez, Dora Lucia Vallejo Ardila, Alejandro Ruíz-Patiño, Diego F Chamorro, July Rodríguez, Darwin A Moreno-Pérez, Hernán Carranza, Jorge Otero, Carlos Vargas, Pilar Archila, Leonardo Rojas, Jairo Zuluaga, Cladelis Rubio, Camila Ordóñez-Reyes, Juan Esteban Garcia-Robledo, Sergio Mejía, Elvira Jaller, Arrieta Oscar, Andrés F Cardona
Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors. JCO global oncology 10 (2024)
Carolina Sotelo-Rodríguez, Dora Lucia Vallejo Ardila, Alejandro Ruíz-Patiño, Diego F Chamorro, July Rodríguez, Darwin A Moreno-Pérez, Hernán Carranza, Jorge Otero, Carlos Vargas, Pilar Archila, Leonardo Rojas, Jairo Zuluaga, Cladelis Rubio, Camila Ordóñez-Reyes, Juan Esteban Garcia-Robledo, Sergio Mejía, Elvira Jaller, Arrieta Oscar, Andrés F Cardona
Molecular Tumor Board Improves Outcomes for Hispanic Patients With Advanced Solid Tumors. JCO global oncology 10 (2024)
Andrés Felipe Cardona, Camila Ordóñez-Reyes, Alejandro Ruíz-Patiño, Juan Esteban Garcia-Robledo, Lucia Zatarain Barron, Gonzalo Recondo, Leonardo Rojas, Luis Corrales-Rodríguez, Claudio Marcelo Martin, Feliciano Barrón, Carolina Sotelo-Rodríguez, July Rodríguez, Luisa Ricaurte, Christian C Rolfo, Jenny Ávila, Diana Mayorga, Pilar Archila, Jorge Otero, Luis Mas, Maritza Bermudez, Tatiana Gamez, Hernán Carranza, Carlos Vargas, Rafael Rosell, Arrieta Oscar
EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP). JCO precision oncology 5 (2022)